Investment Rating - The industry investment rating is "Recommended" with expectations of exceeding the benchmark index by more than 5% in the next 3-6 months [24]. Core Insights - The average new business cost for listed insurance companies has decreased by 65 basis points year-on-year as of H1 2025, driven by adjustments in preset interest rates and the integration of individual insurance channels [2][12]. - The VIF breakeven yield for listed insurance companies is estimated to be in the range of 2.21% to 3.39%, while the NBV breakeven yield is between 1.5% and 2.89% [2]. - The report indicates that the quality of liability management in the insurance industry is gradually improving, with a potential slowdown in the speed of convergence of "interest spread gains" [12]. Summary by Sections New Business Cost Analysis - The average new business cost for listed insurance companies has shown a significant decline, with a decrease of 61 basis points quarter-on-quarter and 65 basis points year-on-year [2]. - The report anticipates that as new business continues to flow in, the existing cost may trend downward [2]. Breakeven Yield Metrics - The VIF breakeven yield for major insurance companies is as follows: China Life (2.43%), Ping An (2.51%), China Pacific (2.21%), New China Life (3.00%), China Re (3.39%), and Sunshine Insurance (2.80%) [3][10]. - The NBV breakeven yield for the same companies is: China Life (1.50%), Ping An (1.73%), China Pacific (1.76%), New China Life (2.68%), China Re (2.89%), and Sunshine Insurance (2.30%) [11]. Investment Recommendations - The report recommends the following order of preference for investment: China Pacific Insurance, China Life H, China Re H, and Sunshine Insurance H. If the equity market continues to outperform expectations, New China Life H is also recommended; if there are signs of recovery in the real estate sector, Ping An is recommended [12].

宏观研究 证 券 研 究 报 告 供需有待 【宏观快评】 外需依然偏强——8 月经济数据前瞻 主要观点 核心观点：展望 8 月，经济的理解框架依然是外需压力缓释后，内部超常规政 策缓退之下的韧性观察。亮点或在出口、生产、服务消费。而制造业投资、基 建投资、耐用品消费、社融受政策节奏影响可能会继续走弱。物价层面，受基 数影响，预计 PPI 同比回升，CPI 同比走弱。 一、出口：非美需求或继续支撑出口偏强 预计 8 月美元计价出口同比 7%左右，进口 2%左右。主要观察：一是，截至 8 月 31 日的四周内，我国港口集装箱吞吐量四周累计同比大幅回升至 9%。二 是，8 月主要经济体（美国、欧元区、日本、韩国、印度、英国、土耳其、俄 罗斯等）制造业 PMI 均值 50.88%，高于 7 月均值 50%。三是，8 月韩国出口 同比降至 1.3%，7 月为 5.9%。不过环比来看，8 月韩国出口环比-3.98%，与 2015-2024 十年同期均值-4%基本持平。8 月上半月，越南主要产品出口同比升 至 18.5%，7 月上半月为 17.1%，7 月全月为 17.7%。 二、亮点：出口、生产、服务消费 1、生产：预计 ...

Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of 27.75 CNY [2][8]. Core Views - The company reported steady revenue growth in the first half of 2025, achieving 1.14 billion CNY in revenue, a year-on-year increase of 28.97%, and a net profit of 101 million CNY, up 2.88% year-on-year [2][8]. - The second quarter saw revenue of 612 million CNY, reflecting a 24.96% year-on-year growth, while net profit slightly decreased by 0.69% to 55 million CNY [2][8]. - The report highlights the company's strong performance in various segments, including rock drilling tools and cutting tools, with significant contributions from acquisitions [8]. Financial Summary - The company is projected to achieve total revenue of 2.36 billion CNY in 2025, with a year-on-year growth rate of 27.0% [4]. - Net profit is expected to reach 229 million CNY in 2025, reflecting a growth rate of 26.6% [4]. - Earnings per share (EPS) are forecasted to be 0.91 CNY in 2025, with a price-to-earnings (P/E) ratio of 19 [4][8]. - The company’s total assets are projected to increase to 4.05 billion CNY by 2025, with a debt-to-equity ratio of 33.4% [9]. Segment Performance - Revenue from rock drilling tools and related services reached 530 million CNY, up 29.60% year-on-year, supported by the acquisition of Drillco [8]. - The hard alloy segment generated 306 million CNY, growing 18.19% year-on-year, despite rising raw material costs [8]. - Cutting tools saw a remarkable growth of 68.23%, with revenue of 161 million CNY, driven by the expansion of production capacity [8]. - The oil service products segment maintained steady growth, contributing 85 million CNY, a 17.52% increase year-on-year [8]. Acquisition Strategy - The company has made strategic acquisitions to enhance its market presence, including the purchase of AMS in Australia and Drillco in South America, which have contributed to revenue growth [8]. - The report emphasizes the successful integration of these acquisitions, which have expanded the company's product lines and market reach [8]. Market Position - The company is recognized as a leading player in the domestic rock drilling tools market, with a strong brand presence in overseas markets such as Australia [8]. - The report indicates that the company has a competitive edge due to its diversified product offerings and strategic acquisitions [8].

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [7]. Core Insights - The company reported a revenue of 1.038 billion yuan for the first half of 2025, representing a year-on-year increase of 27.16%, and a net profit attributable to shareholders of 251 million yuan, up 25.15% year-on-year [1]. - The company continues to expand its digital printing applications, leveraging opportunities from traditional processes transitioning to digital [6]. - The gross margin slightly decreased to 43.79%, while the net margin slightly increased to 25.47% in the first half of 2025 [6]. - The sales of Singlepass models have significantly increased, contributing to a revenue of 670 million yuan from digital printing equipment, a 42.75% year-on-year growth [6]. - The company is actively exploring extended applications of digital printing technology, enhancing its market presence both domestically and internationally [6]. Financial Performance Summary - For the first half of 2025, the company achieved a revenue of 1.038 billion yuan, with a net profit of 251 million yuan [1]. - The projected revenues for 2025, 2026, and 2027 are 2.335 billion yuan, 2.978 billion yuan, and 3.616 billion yuan, respectively, with year-on-year growth rates of 30.4%, 27.5%, and 21.4% [8]. - The projected net profits for the same years are 530 million yuan, 679 million yuan, and 824 million yuan, with growth rates of 27.9%, 28.1%, and 21.4% [8]. - The company’s earnings per share (EPS) are expected to be 2.95 yuan in 2025, 3.78 yuan in 2026, and 4.59 yuan in 2027 [8].

Investment Rating - The report maintains a "Recommended" investment rating for the company [1] Core Views - The company maintains a leading position in silver paste shipments, with high copper paste expected to achieve industrialization breakthroughs [1] - The company is actively promoting low-silver metallization paste development, which is anticipated to benefit from technological iterations [7] Financial Summary - Total revenue for 2024 is projected at 15,351 million, with a year-on-year growth rate of 59.9%. For 2025, revenue is expected to reach 16,578 million, reflecting an 8.0% growth [2] - The net profit attributable to the parent company for 2025 is forecasted at 219 million, a decrease of 39.2% compared to 2024. However, a significant recovery is expected in 2026 with a projected profit of 428 million, representing a 95.6% increase [2] - Earnings per share (EPS) is expected to be 1.54 yuan in 2025, with a projected increase to 3.02 yuan in 2026 and 4.39 yuan in 2027 [2] - The target price for the company's stock is set at 60.36 yuan, compared to the current price of 51.63 yuan [3] Operational Highlights - In the first half of 2025, the company achieved a revenue of 8.34 billion, a year-on-year increase of 9.93%. The net profit for the same period was 7 million, down 70.03% year-on-year [7] - The company shipped 879.86 tons of conductive silver paste in the first half of 2025, with N-type accounting for 95% of the total shipments [7] - The company is advancing the industrialization of high copper paste, which is expected to contribute to performance growth, particularly in the second half of the year [7] - A cash acquisition of 60% of Jiangsu Suote is planned for 696 million, which will enhance market competitiveness and control over the Solamet photovoltaic silver paste business [7]

Investment Rating - The report maintains a "Recommendation" rating for the company, with a target price of 65.30 yuan [2][8]. Core Insights - The company continues to lead the industry in silver paste shipments and is actively expanding its product lineup, particularly in new materials [2][8]. - In the first half of 2025, the company achieved revenue of 6.435 billion yuan, a year-on-year decrease of 4.87%, and a net profit attributable to shareholders of 181 million yuan, down 39.58% year-on-year [8]. - The company’s silver paste shipments exceeded 930 tons in the first half of 2025, with a 96% share of N-type silver paste, indicating a stable increase in market share due to improved operating rates in the downstream photovoltaic cell segment [8]. - The company is also making strides in copper paste products, which have shown promising performance in reliability tests and are expected to launch a second-generation product in Q3 2025 [8]. - The company is enhancing its upstream supply chain to ensure stable raw material supply and reduce costs, which is expected to improve its market competitiveness [8]. Financial Summary - Total revenue projections for the company are as follows: 12.488 billion yuan in 2024, 13.823 billion yuan in 2025, 15.244 billion yuan in 2026, and 16.348 billion yuan in 2027, with year-on-year growth rates of 21.4%, 10.7%, 10.3%, and 7.2% respectively [4][9]. - The net profit attributable to shareholders is projected to be 418 million yuan in 2024, 410 million yuan in 2025, 527 million yuan in 2026, and 642 million yuan in 2027, with growth rates of -5.4%, -1.9%, 28.4%, and 21.9% respectively [4][9]. - The earnings per share (EPS) are expected to be 1.73 yuan in 2024, 1.69 yuan in 2025, 2.18 yuan in 2026, and 2.65 yuan in 2027 [4][9].

Investment Rating - The report maintains a "Strong Buy" rating for the company, expecting it to outperform the benchmark index by over 20% in the next six months [2][17]. Core Views - The company's performance in the first half of 2025 met expectations, with revenue of 519 million yuan, a year-on-year increase of 26.48%, and a net profit attributable to shareholders of 85 million yuan, up 18.80% year-on-year. The second quarter saw revenue of 297 million yuan, a 23.65% increase year-on-year, and a net profit of 56 million yuan, a 2.72% increase year-on-year [2][3]. - The report highlights the company's strong growth potential in the second half of 2025, driven by improved downstream demand and ongoing product performance enhancements [2][3]. Financial Summary - Total revenue projections for 2025-2027 are adjusted to 943 million yuan, 1.198 billion yuan, and 1.522 billion yuan, respectively, with corresponding net profits of 168 million yuan, 229 million yuan, and 300 million yuan [4][9]. - The earnings per share (EPS) are forecasted to be 1.92 yuan, 2.62 yuan, and 3.44 yuan for 2025, 2026, and 2027, respectively [4][9]. - The target price for the company's stock is set at 83.84 yuan, with the current price at 69.69 yuan, indicating significant upside potential [4][9]. Market Performance - The company has shown a strong market performance compared to the CSI 300 index, with a notable increase of 155% over the past 12 months [7]. Business Segments - The report details the revenue contributions from various product lines, with significant margins in CNC blades, while overall tool margins are under pressure due to rising raw material costs [8]. - The company is actively expanding its overseas market presence, with a 20.62% year-on-year increase in overseas revenue, indicating substantial growth opportunities [8]. Strategic Initiatives - The company is focusing on developing tools for key components in humanoid robots, which is a strategic direction for future growth [8].

Report Summary 1. Industry Investment Rating There is no information about the industry investment rating in the report. 2. Core Viewpoints - This year, credit bond ETFs have attracted significant market attention, with active institutional trading and a structural rush to buy related index constituent bonds. Thirteen fund companies have collectively submitted applications for the second batch of Sci - tech Bond ETFs, which are expected to be listed in September. It is worth paying attention to the risks and opportunities of the related index constituent bonds [1][10]. - The short - term risk of significant over - decline of the Sci - tech Bond ETF index constituent bonds is relatively small. The new batch of Sci - tech Bond ETFs will bring new allocation funds, and the supply growth momentum has slowed down. After the second - batch listing, the excess spread of constituent bonds is unlikely to return to the high level in the first half of the year. The excess spread of constituent bonds is expected to further compress, but the space is limited. Some individual bonds' structural opportunities can be focused on [5][44][45]. 3. Summary by Directory 3.1 Sci - tech Bond ETF and Related Constituent Bonds' Recent Market Performance - **Discount status**: Since mid - to late July, Sci - tech Bond ETFs have been in a discount state, with the discount rate mainly between 0.05% - 0.4%. Although there was some repair in early August and late August when the bond market sentiment improved marginally, they have not turned into a premium state. Similar ETFs also experienced discounts during previous bond market adjustments and then recovered [2][11]. - **Differentiated performance of short - term and long - term constituent bonds**: The excess spreads of 3 - year - within and 3 - 5 - year constituent bonds fluctuate with the bond market, with a larger amplitude than the same - term and same - grade medium - term notes. Currently, they are about 2 - 3BP higher than the previous low on average. The excess spread of over - 5 - year constituent bonds continued to narrow in August, but there was a catch - up decline at the end of the month. There is a need to pay attention to the possibility of further catch - up decline [3][14][16]. - **Adjustment amplitude comparison**: The recent adjustment amplitude of the underlying constituent bonds of the benchmark - making credit bond ETF index is slightly larger than that of the Sci - tech Bond ETF index constituent bonds. This may be due to the better liquidity of benchmark - making credit bond varieties and the fact that the listing of Sci - tech Bond ETFs has squeezed the allocation demand for benchmark - making credit bond ETFs to some extent [3][30]. 3.2 Recent Supply - Demand Structure of Index Constituent Bonds - **Supply side**: Since the introduction of the new Sci - tech Bond policy in May, the issuance of Sci - tech Bonds has been booming, and the scale has increased significantly. Although the recent issuance scale has declined, it remains at a relatively high level. As of the end of August, the balance of the constituent bonds of the CSI AAA Sci - tech Bond index was close to 1.25 trillion yuan, an increase of nearly 277.8 billion yuan compared to the end of April [32]. - **Demand side**: After the listing of Sci - tech Bond ETFs, the scale expanded rapidly, but the recent growth rate has been relatively flat. This may be because the yield of index constituent bonds has declined rapidly, reducing their cost - effectiveness, and the secondary - market credit ETFs are in a discount state during the recent bond market adjustment, weakening the primary - market subscription sentiment [4][35]. 3.3 Opportunities and Risks of Related Index Constituent Bonds after the Application for the Second Batch of Sci - tech Bond ETFs - **Tracking index types**: The second - batch Sci - tech Bond ETFs mainly track the CSI AAA, Shanghai Stock Exchange AAA, and Shenzhen Stock Exchange AAA Sci - tech Bond indexes, with 9, 3, and 1 fund respectively [39]. - **Expected listing time**: If referring to the application - approval process of the first batch, the second batch of Sci - tech Bond ETFs is expected to be issued and listed in September [41][43]. - **Opportunities and risks**: The short - term risk of significant over - decline of the index constituent bonds is small. The excess spread of constituent bonds is expected to further compress, but the space is limited. Attention can be paid to individual bonds with relatively high excess spread levels and large recent declines to seek potential excess returns [5][44][45].

Investment Rating - The report maintains a "Recommended" rating for Kangyuan Pharmaceutical with a target price of 20.8 CNY [2][7]. Core Views - The company's performance is under short-term pressure due to marketing reforms and demand fluctuations, with 1H25 revenue at 1.64 billion CNY (-27.3% YoY) and net profit at 140 million CNY (-40.1% YoY) [2][7]. - Despite the challenges, the company is making steady progress in R&D, with several new drugs in various stages of clinical trials [2][7]. - The report anticipates a new development cycle driven by marketing efficiency reforms and breakthroughs in innovative drugs [2][7]. Financial Summary - **Revenue and Profitability**: - Total revenue for 2024 is projected at 3.898 billion CNY, with a YoY growth rate of -19.9%. For 2025, revenue is expected to remain flat at 3.897 billion CNY, followed by growth of 10.0% in 2026 and 10.1% in 2027 [2][8]. - Net profit for 2024 is estimated at 392 million CNY, with a YoY decline of -27.0%. The net profit is expected to stabilize in 2025 and grow by 15.0% in 2026 and 15.1% in 2027 [2][8]. - **Earnings Per Share (EPS)**: - EPS is projected to be 0.69 CNY in 2024, remaining the same in 2025, and increasing to 0.80 CNY in 2026 and 0.92 CNY in 2027 [2][8]. - **Valuation Ratios**: - The price-to-earnings (P/E) ratio is expected to be 25 in 2025, decreasing to 22 in 2026 and 19 in 2027. The price-to-book (P/B) ratio is projected to decline from 2.0 in 2025 to 1.7 in 2027 [2][8]. R&D Progress - The company has made significant advancements in its R&D pipeline, with multiple new drugs in various clinical phases, including traditional Chinese medicine and chemical drugs [2][7]. - Notable projects include the approval of Yunu Jian granules and several new drug applications, with a focus on obesity and Alzheimer's disease treatments [2][7].

Investment Rating - The report maintains a "Recommendation" rating for the company, indicating an expectation to outperform the benchmark index by 10%-20% over the next six months [17]. Core Insights - The company reported a significant increase in revenue from the automotive sector, with a year-on-year growth of 109.60% in the first half of 2025. The total revenue for H1 2025 reached 348 million yuan, a 7.48% increase compared to the previous year, while the net profit attributable to the parent company decreased by 69.84% to 12 million yuan [1][7]. - The report highlights the acceleration of the commercialization of all-solid-state battery insulation glue frame printing solutions, which is expected to enhance operational efficiency and innovation [7]. - The company is experiencing a decline in net profit primarily due to the increasing proportion of lower-margin automotive business and rising depreciation and operational costs from ongoing projects [7]. Financial Summary - For the first half of 2025, the company achieved a gross profit margin of 42.63% and a net profit margin of 3.61%. In Q2 2025, revenue was 194 million yuan, reflecting a 3.35% year-on-year increase and a 26.97% quarter-on-quarter increase [1]. - The projected total revenue for 2025-2027 is estimated at 951 million, 1,214 million, and 1,522 million yuan, respectively, with year-on-year growth rates of 27.5%, 27.7%, and 25.3% [3][7]. - The forecasted net profit for the same period is expected to be 66 million, 135 million, and 172 million yuan, with a notable rebound in 2026 and 2027 after a projected decline in 2025 [3][7]. Segment Performance - The 3C segment generated 244 million yuan in revenue during H1 2025, with a 3.27% increase in mobile phone and accessories sales. The company has expanded its collaboration with major North American consumer electronics clients [7]. - The automotive segment's revenue in H1 2025 was 98 million yuan, with a significant increase in orders due to the successful development of exterior parts for mainstream vehicle models [7]. - The new energy segment has made progress with the development of integrated solutions for all-solid-state battery insulation glue frame printing, which is currently in the joint verification phase with leading downstream manufacturers [7].